MetaVia Advances Clinical Trials for DA-1726
MetaVia Inc. (Nasdaq: MTVA), a biotechnology company dedicated to transforming the treatment of cardiometabolic diseases, has recently achieved an important milestone in its Phase 1 clinical trial of the drug DA-1726. The company has extended the trial period from 4 weeks to 8 weeks for the 48 mg multiple ascending dose (MAD) cohort and has administered the fifth weekly dose to the first participating patient.
DA-1726 is characterized as a dual oxyntomodulin (OXM) analog that engages two critical receptors, glucagon-like peptide-1 (GLP-1) and glucagon receptors (GCGR), which are pivotal in addressing obesity. The extension of the trial is designed to provide insights into the drug's long-term safety, tolerability, and efficacy. In particular, MetaVia aims to explore the maximum tolerated dose without titration over this longer span.
Understanding the Objectives of the Extended Trial
In a statement, Hyung Heon Kim, President and CEO of MetaVia, outlined the significance of the 4-week extension, emphasizing the potential to gather more comprehensive data on DA-1726. This information could enhance its positioning against current obesity treatments and those in advanced stages of clinical trials. The company aims to fully assess DA-1726's therapeutic profile, including its impact on primary and secondary endpoints such as safety, tolerability, body weight, waist circumference, and body mass index (BMI).
Previous data from the 32 mg dose indicated promising outcomes, with participants experiencing a mean weight loss of 4.3% and some achieving up to 6.3% by Day 26. Additionally, 83% of the patients reported early satiety, and significant waist reductions were noted by Day 33. This data bolsters expectations that DA-1726 may deliver superior tolerability compared to existing GLP-1 therapies.
Trial Design and Objectives
The Phase 1 trial itself is structured as a randomized, double-blind, placebo-controlled study aimed at assessing the safety, pharmacokinetics, and pharmacodynamics of DA-1726 among obese, otherwise healthy subjects. Participants were enrolled with a BMI ranging from 30 to 45 kg/m², structured in cohorts where each subject either received the drug or a placebo across several weekly administrations.
With the extension, subjects will experience an additional four weekly doses of DA-1726, bringing the total exposure duration to 8 weeks. Primary endpoints focus on evaluating the safety and tolerability by monitoring adverse reactions, while secondary endpoints are centered around the pharmacokinetics of the drug at its highest doses.
Significance of DA-1726 in Obesity Treatment
DA-1726 is particularly notable for being an oxyntomodulin (OXM) analog that is expected to be administered once weekly via subcutaneous injection. Its dual-action mechanism promotes weight loss by suppressing appetite and enhancing energy expenditure. In preclinical studies, DA-1726 has shown superior weight loss compared to several existing treatments, demonstrating an ability to deliver positive results while encouraging healthier metabolic responses.
The Future of MetaVia's Development
Looking ahead, MetaVia continues to advance its research efforts, not just with DA-1726, but also with DA-1241, which aims to address Metabolic Dysfunction-Associated Steatohepatitis (MASH). This commitment to innovation in the field of cardiometabolic disorders places MetaVia at the forefront of biotechnology and therapeutic solutions.
With the ongoing development of DA-1726 and its potential applications, the industry watches closely for the forthcoming top-line data that is expected in the near future. The anticipation surrounding this data will be crucial for validating DA-1726's efficacy and safety, positioning it as a promising candidate in the landscape of obesity treatments.
Frequently Asked Questions
What is the aim of MetaVia's Phase 1 clinical trial for DA-1726?
The trial aims to evaluate the safety, tolerability, and efficacy of DA-1726 in obese patients over an extended period of 8 weeks.
How does DA-1726 work?
DA-1726 acts as a dual agonist of GLP-1 and glucagon receptors, leading to weight loss through reduced appetite and increased energy expenditure.
What were the significant outcomes from the previous 32 mg dose studies?
Participants experienced a mean weight loss of 4.3%, reported early satiety in 83% of cases, and noted significant waist reductions.
Why is the extension to 8 weeks significant for the clinical trial?
This additional time allows for a more robust evaluation of the drug’s therapeutic profile and its long-term safety and efficacy.
What other products is MetaVia developing besides DA-1726?
MetaVia is also working on DA-1241, aimed at treating MASH and promoting healthier metabolic responses.
